Banner Image for Directory


Toh Han Chong


Academic Vice Chair, Strategic Partnerships, Oncology Academic Clinical Programme


Education Qualifications: ​BSc (London), MB BCHIR (Cambridge), MRCP (UK), FRCP (Edin), FAMS

Dr Toh is Senior Consultant and former Head at the Department of Medical Oncology and now Deputy Medical Director (Strategic Partnerships), National Cancer Centre, Singapore. He graduated from the University of London, UK with an intercalated Bachelor of Science in 'Infection and Immunity' from St Mary's Hospital Medical School and qualified as a medical doctor from University of Cambridge, UK. Dr Toh obtained his Fellowship of the Royal College of Physicians in 2003. He received his medical oncology fellowship training at the Singapore General Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, USA and at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA. Dr Toh is also alumni at the Harvard Business School. He is currently the vice-chairman of the Oncology Academic Clinical Program (ACP) for Education.

He is a recipient of the National Clinician Scientist Award for his pioneering work in cell therapy for cancer. He conducted the first cancer vaccine and T cell therapy clinical trials in Singapore, and continues to work actively in the field of cancer immunotherapy, immunology and inflammation. He also had a strong interest in drug development for gastrointestinal cancers including colon and liver cancer. Dr Toh is an Associate Professor and College Master at the Duke-NUS Medical School. He is also an adjunct Principal Investigator at the Institute of Molecular and Cell Biology, A*STAR. He was a council member in the Singapore Medical Association and the Singapore College of Physicians.

Professional Appointments and Committee Memberships:

2014- Current Adjunct PI, Institute of Molecular and Cell Biology, A*STAR, Biopolis Singapore
2013- Current Vice Chairman, Oncology ACP for Education
2013- Current Deputy Director, National Cancer Centre Singapore
2011- Current Associate Professor, Cancer & Stem Cell Biology Program, Duke-NUS GMS, Singapore
2011- Current Chairman, Cell Tissue-Based Therapy Committee, National Cancer Centre Singapore
2011- Current Chairman, Cell Tissue-Based Therapy Committee, National Cancer Centre Singapore
2010- Current College Master for Eugene Stead College, Duke-NUS GMS
2009- 2013 Head, Division of Medical Oncology, National Cancer Centre Singapore
2004- Current Senior Consultant, Division of Medical Oncology, National Cancer Centre, Singapore


2016 Duke-SingHealth AM-ETHOS Mentoring Award to Duke University Health System
2016 Outstanding Poster Presentation Award, Gordon Research Conference for Nasopharyngeal Carcinoma, Hong Kong
2009 National Medical Research Council Clinician Scientist Award
2008 Duke-NUS Graduate Medical School Best Teacher Award (Molecules and Cells)
2004 National Excellent Service Award (Star Award)
1999- 2000 Singapore Cancer Society Overseas Fellowship Award.
1998-1999 Singapore General Hospital Fellowship Award.
1997-1998 Singapore Health Manpower Development Plan Fellowship Award.
1996 First Prize, 7th Singapore General Hospital Annual Scientific Meeting Commemorative Essay Competition.
1981-1983 United World College Scholarship, to the Lester B. Pearson College of the Pacific, British Columbia, Canada to read for the International Baccalaureate.

Research Interests:

  • Cancer Immunology
  • Cancer Immunotherapy
  • Gastrointestinal Cancer
  • Hepatocellular Carcinoma and Clinical Trials

Selected Publications:

Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Garnelo M, Tan A, Her Z, Yeong J, Lim CJ, Chen J, Lim KH, Weber A, Chow P, Chung A, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Chen Q, Abastado JP, Chew V. Gut. 2017 Feb;66(2):342-35

Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis. Ang WX, Li Z, Chi Z, Du SH, Chen C, Tay JC, Toh HC, Connolly JE, Xu XH, Wang S. Oncotarget. 2017 Jan 10.

A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). Tai WM, Yong WP, Lim C, Low LS, Tham CK, Koh TS, Ng QS, Wang WW, Wang LZ, Hartano S, Thng CH, Huynh H, Lim KT, Toh HC, Goh BC, Choo SP. Ann Oncol. 2016 Dec;27(12):2210-2215.

National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma. • Chow PK, Choo SP, Ng DC, Lo RH, Wang ML, Toh HC, Tai DW, Goh BK, Wong JS, Tay KH, Goh AS, Yan SX, Loke KS, Thang SP, Gogna A, Too CW, Irani FG, Leong S, Lim KH, Thng CH. Liver Cancer. 2016 Apr;5(2):97-106.

Longitudinal metabolic imaging of hepatocellular carcinoma in transgenic mouse models identifies acylcarnitine as a potential biomarker for early detection. Yaligar J, Teoh WW, Othman R, Verma SK, Phang BH, Lee SS, Wang WW, Toh HC, Gopalan V, Sabapathy K, Velan SS. Sci Rep. 2016 Feb 2;6:20299.

Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S. Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial. J Clin Oncol. 2015 Jan 10;33(2):172-9.

Bard-Chapeau EA, Nguyen AT, Rust AG, Sayadi A, Lee P, Chua BQ, New LS, de Jong J, Ward JM, Chin CK, Chew V, Toh HC, Abastado JP, Benoukraf T, Soong R, Bard FA, Dupuy AJ, Johnson RL, Radda GK, Chan EC, Wessels LF, Adams DJ, Jenkins NA, Copeland NG (2014) Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. Nat Genet 46(1) : 24-32

Chua C, Tan IB, Choo SP, Toh HC (2013) Increased a-Fetoprotein Likely Induced by Complementary Health Products. J Clin Oncol 31(6) : e80-2

Chew V, Tow C, Huang C, Bard-Chapeau E, Copeland NG, Jenkins NA, Weber A, Lim KH, Toh HC, Heikenwalder M, Ng IO, Nardin A, Abastado JP (2012) Toll-Like Receptor 3 Expressing Tumor Parenchyma and Infiltrating Natural Killer Cells in Hepatocellular Carcinoma Patients. J Natl Cancer Inst 104(23) : 1796-807

Chia WK, Ali R, Toh HC (2012) Aspirin as adjuvant therapy for colorectal cancer-reinterpreting paradigms. Nat Rev Clin Oncol 9(10) : 561-70